In the treatment of chronic hepatitis C, the addition of Tα1 to IFNα, pegylated or not, and ribavirin in patients who have failed prior interferon and ribavirin treatment (66–69) has shown promising results. The gene discussed is IFNA2; the disease is chronic hepatitis C virus infection.